Login Register Cart 0
Generic placeholder image

Current Nutrition & Food Science

Editor-in-Chief

ISSN (Print): 1573-4013
ISSN (Online): 2212-3881

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Mini-Review Article

The Use of Berberine in Diabetes and Metabolic Syndrome: Two Sides of the Same Coin. A Bibliometric Analysis

Author(s): Vittoria Infantino, Antonella Riva, Giovanna Petrangolini, Pietro Allegrini, Simone Perna, Giancarlo Iannello, Gabriella Peroni*, Clara Gasparri and Mariangela Rondanelli

Volume 18, Issue 3, 2022

Published on: 14 January, 2022

Page: [240 - 247] Pages: 8

DOI: 10.2174/1573401317666211125101041

Price: $65

Abstract

The increased prevalence of obesity, metabolic syndrome and type 2 diabetes has prompted scientists to look for new active and safe molecules that may help the prevention of metabolic disorders: hyperglycemia, insulin-resistance and dyslipidemia. Berberine is an alkaloid compound derived from plants, and it is largely used in traditional Chinese medicine. The aim of this study is to investigate in SCOPUS and Web of Science (WOS) databases how the scientists focused on the use of berberine against metabolic disorders, in human subjects. We carried A bibliometric analysis of scientific literature and performed 2 searches: 1) “Berberine” AND “Diabetes” AND “Diabetes Type 2”, 2) “Berberine” AND “Metabolic Syndrome”, both in ARTICLE (Title/Abstract/Keyword) with a time limitation of 1st January, 2000 through 31st December, 2018, with the filter on “HUMAN” AND/OR “HUMANS”. The research sorted out 500 papers, finding about 300 (60 %) in the first search definition and 200 (40 %) in the second. The refined research sorted out 46 papers regarding the use of berberine in diabetes, and 40 articles on the use of the alkaloid compound in metabolic syndrome. For both topics, we found increasing interest between 2008 and 2009, with citation trends in a constant crescendo in the overall period studied. These findings underlined that berberine is a safe and interesting botanical compound, especially against chronic-metabolic disorder that affects billions of people globally, and emphasized that scientists are interested in searching for long-term therapies that show no major adverse effects.

Keywords: Berberine, diabetes, metabolic syndrome, bioactivity, bibliometrics, humans.

« Previous Next »
Graphical Abstract

[1]
International diabetes federation IDF Diabetes Atlas. Eighth ed. International diabetes federation: Brussels, Belgium 2017. ISBN 9782930229874.
[2]
Fiocca L, Musumeci G, Rossini R, Staffiere E, Valsecchi O, Gavazzi A. La sindrome metabolica : Impatto sul rischio cardiovascolare. G Ital Cardiol 2010; 11: 29S-32S.
[3]
Fogarty S, Hardie DG. Development of protein kinase activators: AMPK as a target in metabolic disorders and cancer. Biochim Biophys Acta 2010; 1804(3): 581-91.
[http://dx.doi.org/10.1016/j.bbapap.2009.09.012] [PMID: 19778642]
[4]
Wang Y, Fu X, Xu J, Wang Q, Kuang H. Systems pharmacology to investigate the interaction of berberine and other drugs in treating polycystic ovary syndrome. Sci Rep 2016; 6: 28089.
[http://dx.doi.org/10.1038/srep28089] [PMID: 27306862]
[5]
Yin J, Ye J, Jia W. Effects and mechanisms of berberine in diabetes treatment. Acta Pharm Sin B 2012; 2: 327-34.
[http://dx.doi.org/10.1016/j.apsb.2012.06.003]
[6]
Guido D, Morandi G, Palluzzi F, Borroni B. Telling the story of frontotemporal dementia by bibliometric analysis. J Alzheimers Dis 2015; 48(3): 703-9.
[http://dx.doi.org/10.3233/JAD-150275] [PMID: 26402093]
[7]
Morandi G, Guido D, Tagliabue A. A bibliometric study of scientific literature on the dietary therapies for epilepsy in Scopus. Nutr Neurosci 2015; 18(5): 201-9.
[http://dx.doi.org/10.1179/1476830514Y.0000000118] [PMID: 24628043]
[8]
StataCorp. Stata statistical software: Release 12. College station, TX: StataCorp LP 2011.
[9]
Garfield E. Introducing citation classics: The human side of scientific reports. Curr Contents 1977; 1: 5-7.
[10]
Hirsch JE. An index to quantify an individual’s scientific research output. PNAS 2005; 102(46): 16569-72.
[http://dx.doi.org/10.1073/pnas.0507655102]
[11]
Rondanelli M, Perna S, Peroni G, Guido D. A bibliometric study of scientific literature in Scopus on botanicals for treatment of androgenetic alopecia. J Cosmet Dermatol 2016; 15(2): 120-30.
[http://dx.doi.org/10.1111/jocd.12198] [PMID: 26608588]
[12]
Perna S, Peroni G, Miccono A, et al. Multidimensional effects of soy isoflavone by food or supplements in menopause women: A systematic review and bibliometric analysis. Nat Prod Commun 2016; 11(11): 1733-40.
[http://dx.doi.org/10.1177/1934578X1601101127] [PMID: 30475519]
[13]
Scimago Journal Rank. Available from:. https://www.scimagojr.com/ (Accessed on Feb 5, 2019).
[14]
Yin J, Xing H, Ye J. Efficacy of berberine in patients with type 2 diabetes mellitus. Metabolism 2008; 57(5): 712-7.
[http://dx.doi.org/10.1016/j.metabol.2008.01.013] [PMID: 18442638]
[15]
Zhang L, Lv Yamin. Ye S mao, Dong X yun. Mechanism of exacerbation of colonic damage in experimental colitis treated with celecoxib. Beijing Da Xue Xue Bao 2008; 40: 195-9.
[PMID: 18458699]
[16]
Jeong HW, Hsu KC, Lee J-W, et al. Berberine suppresses proinflammatory responses through AMPK activation in macrophages. Am J Physiol Endocrinol Metab 2009; 296(4): E955-64.
[http://dx.doi.org/10.1152/ajpendo.90599.2008] [PMID: 19208854]
[17]
Zhang H, Wei J, Xue R, et al. Berberine lowers blood glucose in type 2 diabetes mellitus patients through increasing insulin receptor expression. Metabolism 2010; 59(2): 285-92.
[http://dx.doi.org/10.1016/j.metabol.2009.07.029] [PMID: 19800084]
[18]
Gu Y, Zhang Y, Shi X, et al. Effect of traditional Chinese medicine berberine on type 2 diabetes based on comprehensive metabonomics. Talanta 2010; 81(3): 766-72.
[http://dx.doi.org/10.1016/j.talanta.2010.01.015] [PMID: 20298851]
[19]
Kong W-J, Zhang H, Song D-Q, et al. Berberine reduces insulin resistance through protein kinase C-dependent up-regulation of insulin receptor expression. Metabolism 2009; 58(1): 109-19.
[http://dx.doi.org/10.1016/j.metabol.2008.08.013] [PMID: 19059538]
[20]
Xie W, Zhao Y, Zhang Y. Traditional chinese medicines in treatment of patients with type 2 diabetes mellitus. Evid Based Complement Alternat Med 2011; 2011726723
[http://dx.doi.org/10.1155/2011/726723] [PMID: 21584252]
[21]
Di Pierro F, Villanova N, Agostini F, Marzocchi R, Soverini V, Marchesini G. Pilot study on the additive effects of berberine and oral type 2 diabetes agents for patients with suboptimal glycemic control. Diabetes Metab Syndr Obes 2012; 5: 213-7.
[http://dx.doi.org/10.2147/DMSO.S33718] [PMID: 22924000]
[22]
Lian F, Li G, Chen X, et al. Chinese herbal medicine Tianqi reduces progression from impaired glucose tolerance to diabetes: A double-blind, randomized, placebo-controlled, multicenter trial. J Clin Endocrinol Metab 2014; 99(2): 648-55.
[http://dx.doi.org/10.1210/jc.2013-3276] [PMID: 24432995]
[23]
Chao M, Zou D, Zhang Y, et al. Improving insulin resistance with traditional Chinese medicine in type 2 diabetic patients. Endocrine 2009; 36(2): 268-74.
[http://dx.doi.org/10.1007/s12020-009-9222-y] [PMID: 19728183]
[24]
Tiganis T. PTP1B and TCPTP--nonredundant phosphatases in insulin signaling and glucose homeostasis. FEBS J 2013; 280(2): 445-58.
[http://dx.doi.org/10.1111/j.1742-4658.2012.08563.x] [PMID: 22404968]
[25]
Wei W, Zhao H, Wang A, et al. A clinical study on the short-term effect of berberine in comparison to metformin on the metabolic characteristics of women with polycystic ovary syndrome. Eur J Endocrinol 2012; 166(1): 99-105.
[http://dx.doi.org/10.1530/EJE-11-0616] [PMID: 22019891]
[26]
Trimarco B, Benvenuti C, Rozza F, Cimmino CS, Giudice R, Crispo S. Clinical evidence of efficacy of red yeast rice and berberine in a large controlled study versus diet. Med J Nutrition Metab 2011; 4(2): 133-9.
[http://dx.doi.org/10.3233/s12349-010-0043-6] [PMID: 21909461]
[27]
Di Pierro F, Putignano P, Villanova N, Montesi L, Moscatiello S, Marchesini G. Preliminary study about the possible glycemic clinical advantage in using a fixed combination of Berberis aristata and Silybum marianum standardized extracts versus only Berberis aristata in patients with type 2 diabetes. Clin Pharmacol 2013; 5: 167-74.
[http://dx.doi.org/10.2147/CPAA.S54308] [PMID: 24277991]
[28]
Pérez-Rubio KG, González-Ortiz M, Martínez-Abundis E, Robles-Cervantes JA, Espinel-Bermúdez MC. Effect of berberine administration on metabolic syndrome, insulin sensitivity, and insulin secretion. Metab Syndr Relat Disord 2013; 11(5): 366-9.
[http://dx.doi.org/10.1089/met.2012.0183] [PMID: 23808999]
[29]
Cicero A, Derosa G, Bove M, Imola F, Borghi C, Gaddi A. Long-term effectiveness and safety of a nutraceutical based approach to reduce cholesterolemia in statin intolerant subjects with and without metabolic syndrome. Curr Top Nutraceutical Res 2009; 7: 121-5.
[30]
Yang J, Yin J, Gao H, et al. Berberine improves insulin sensitivity by inhibiting fat store and adjusting adipokines profile in human preadipocytes and metabolic syndrome patients. Evid Based Complement Alternat Med 2012; 2012363845
[http://dx.doi.org/10.1155/2012/363845] [PMID: 22474499]
[31]
Gonnelli S, Caffarelli C, Stolakis K, Cuda C, Giordano N, Nuti R. Efficacy and tolerability of a nutraceutical combination (red yeast rice, policosanols, and berberine) in patients with low-moderate risk hypercholesterolemia: A double-blind, placebo-controlled study. Curr Ther Res Clin Exp 2014; 77: 1-6.
[http://dx.doi.org/10.1016/j.curtheres.2014.07.003] [PMID: 26649075]
[32]
Cicero AF, Rosticci M, Parini A, et al. Short-term effects of a combined nutraceutical of insulin-sensitivity, lipid level and indexes of liver steatosis: A double-blind, randomized, cross-over clinical trial. Nutr J 2015; 14: 30.
[http://dx.doi.org/10.1186/s12937-015-0019-y] [PMID: 25886384]
[33]
Zhang Y, Li X, Zou D, et al. Treatment of type 2 diabetes and dyslipidemia with the natural plant alkaloid berberine. J Clin Endocrinol Metab 2008; 93(7): 2559-65.
[http://dx.doi.org/10.1210/jc.2007-2404] [PMID: 18397984]
[34]
Zhaojie M, Ming Z, Shengnan W, et al. Amorphous solid dispersion of berberine with absorption enhancer demonstrates a remarkable hypoglycemic effect via improving its bioavailability. Int J Pharm 2014; 467(1-2): 50-9.
[http://dx.doi.org/10.1016/j.ijpharm.2014.03.017] [PMID: 24607213]
[35]
Yu Y, Hao G, Zhang Q, et al. Berberine induces GLP-1 secretion through activation of bitter taste receptor pathways. Biochem Pharmacol 2015; 97(2): 173-7.
[http://dx.doi.org/10.1016/j.bcp.2015.07.012] [PMID: 26206195]
[36]
Di Pierro F, Bellone I, Rapacioli G, Putignano P. Clinical role of a fixed combination of standardized Berberis aristata and Silybum marianum extracts in diabetic and hypercholesterolemic patients intolerant to statins. Diabetes Metab Syndr Obes 2015; 8: 89-96.
[http://dx.doi.org/10.2147/DMSO.S78877] [PMID: 25678808]
[37]
An Y, Sun Z, Zhang Y, Liu B, Guan Y, Lu M. The use of berberine for women with polycystic ovary syndrome undergoing IVF treatment. Clin Endocrinol (Oxf) 2014; 80(3): 425-31.
[http://dx.doi.org/10.1111/cen.12294] [PMID: 23869585]
[38]
McCarty MF, O’Keefe JH, DiNicolantonio JJ. Red yeast rice plus berberine: Practical strategy for promoting vascular and metabolic health. Altern Ther Health Med 2015; 21(2): 40-5.
[PMID: 26308759]
[39]
De Castro-Orós I, Solà R, Valls RM, et al. Genetic variants of LDLR and PCSK9 associated with variations in response to antihypercholesterolemic effects of armolipid plus with berberine. PLoS One 2016; 11(3)e0150785
[http://dx.doi.org/10.1371/journal.pone.0150785] [PMID: 27015087]
[40]
Zhang BB, Zhou G, Li C. AMPK: An emerging drug target for diabetes and the metabolic syndrome. Cell Metab 2009; 9(5): 407-16.
[http://dx.doi.org/10.1016/j.cmet.2009.03.012] [PMID: 19416711]
[41]
Hardie DG. AMPK: A target for drugs and natural products with effects on both diabetes and cancer. Diabetes 2013; 62(7): 2164-72.
[http://dx.doi.org/10.2337/db13-0368] [PMID: 23801715]
[42]
Hardie DG. Sensing of energy and nutrients by AMP-activated protein kinase. Am J Clin Nutr 2011; 93(4): 891S-6.
[http://dx.doi.org/10.3945/ajcn.110.001925] [PMID: 21325438]
[43]
Gyasi RM, Phillips DR. Aging and the rising burden of noncommunicable diseases in sub-saharan Africa and other low- and middle-income countries: A call for holistic action. Gerontologist 2019; 60(5): 806-11.
[http://dx.doi.org/10.1093/geront/gnz102] [PMID: 31322656]
[44]
Balaz M, Wolfrum C. Statins: Benefits and risks revisited. Aging 2019; 11(13): 4300-2.
[http://dx.doi.org/10.18632/aging.102056]
[45]
Roy R, Ajithan A, Joseph A, Mateti UV. Statin-induced new onset of diabetes in dyslipidemic patients: A retrospective study. Postgrad Med 2019; 131(6): 383-7.
[46]
Ong M, Peng J, Jin X, Qu X. Chinese herbal medicine for the optimal management of polycystic ovary syndrome. Am J Chin Med 2017; 45(3): 405-22.
[http://dx.doi.org/10.1142/S0192415X17500252] [PMID: 28359195]
[47]
Catapano AL, Graham I, De Backer G, et al. 2016 ESC/EAS guidelines for the management of dyslipidaemias. Eur Heart J 2016; 37(39): 2999-3058.
[http://dx.doi.org/10.1093/eurheartj/ehw272] [PMID: 27567407]
[48]
Poli A, Barbagallo CM, Cicero AFG, et al. Nutraceuticals and functional foods for the control of plasma cholesterol levels. An intersociety position paper. Pharmacol Res 2018; 134: 51-60.
[http://dx.doi.org/10.1016/j.phrs.2018.05.015] [PMID: 29859248]

Rights & Permissions Print Cite
Article Metrics
60
1
© 2024 Bentham Science Publishers | Privacy Policy